1043546-64-0

Basic information

• Product Name: 3,4-difluorocinnamoyl chloride
• CAS NO: 1043546-64-0
• Molecular Weight: 202.588
• Mol File: 1043546-64-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3,4-difluorocinnamoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-difluorocinnamoyl chloride(1043546-64-0)
• EPA Substance Registry System: 3,4-difluorocinnamoyl chloride(1043546-64-0)

Safety Data

• Hazardous Substances Data: 1043546-64-0(Hazardous Substances Data)

Upstream product

• 34036-07-2 3,4 difluorobenzaldehyde 
• 112897-97-9 (E)-3-(3,4-difluorophenyl)acrylic acid 
• 152152-17-5 3-(3,4-difluorophenyl)-2-propenoic acid 

Downstream Products

• 161712-77-2 5,6-difluoroindan-1-one 
• 1006614-49-8 (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine 
• 274693-26-4 [3aR-[3aα,4α,6α,(1R,2S),6aα]]-2-[6-[[[7-(2-(3,4-difluorophenyl)cyclopropyl)]amino-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenteno-1,3-dioxolan-4-yl]oxy]ethanol 
• 220352-36-3 trans-(1R,2R)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid 
• 274693-27-5 ticagrelor 

Relevant articles and documents

New coumarin/sulfocoumarin linked phenylacrylamides as selective transmembrane carbonic anhydrase inhibitors: Synthesis and in-vitro biological evaluation

Two novel series of phenylacrylamide linked coumarins and sulfocoumarins (6a-p, 8a-i, and 14a-g) were synthesized and evaluated against four physiologically relevant human carbonic anhydrases (hCAs, EC 4.2.1.1), isoforms hCA I, hCA II, hCA IX and hCA XII for their inhibitory action. All new compounds when screened for carbonic anhydrase inhibitory activity have shown selective inhibition towards the tumor associated isoforms hCA IX and XII over CA I and II, with inhibition constants in the submicromolar to low nanomolar range. Compound 6b and 14g exhibited significant inhibition with low nanomolar potency against hCA IX, whereas 6k was effective against hCA XII. Compounds 6b, 14g and 6k may be considered as lead molecules for future development of cancer therapeutics based on a novel mechanism of action.

BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu- opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.